Learn More
OBJECTIVE Recent research suggests that other surrogate markers than QTc, including QTc dispersion and Tpeak-Tend, may better correlate with cardiac arrhythmia risk. While sertindole significantly prolongs the QTc interval, the effects on other markers of arrhythmia risk, such as QTc dispersion and Tpeak-Tend are unknown. METHOD Digital 12-lead ECG was(More)
The QTc interval plays an important role in pre-market testing of new drugs, but the intrinsic variability of the measurement is critical. Most arrhythmogenic drugs inhibit the I Kr current and cause both QTc prolongation and changes in T-wave morphology. Quantification of T-wave morphology may be useful in drug testing, but no robust method exists for this(More)
The electrocardiographic QT interval is the only widely used surrogate marker of repolarization abnormality in drug trials. However, numerous basic and clinical studies have provided evidence that disturbed ventricular repolarization is reflected not only in the duration of the QT interval but also in the shape of the electrocardiographic T-wave. Thus, in(More)
Drugs that prolong the QTc interval to clinically relevant magnitudes are likely to be proarrhythmic if they also produce relevant changes in the morphology of repolarization waveforms. Concurrent analyses of QTc and the T-wave Morphology Combination Score (MCS) have already shown how this approach can improve characterization of repolarization effects for(More)
QT interval prolongation is one of the most common causes of delays and non-approvals in drug development due to the qualitative relationship between this interval and Torsade de Pointes (TdP) arrhythmia. However, not all drugs that prolong the QT interval to the same extent carry the same risk for TdP. Other indications, such as abnormal T-wave morphology,(More)
  • 1